Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Can combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, produce durable clinical responses in patients with cancer?
The importance of targeting toposimerase II (TOP2) for the treatment of cancer is not a new concept; however, understanding of the biological functions of this enzyme has lagged behind the use of the drugs to target it. This Review discusses what we now know about the functions of TOP2.
The ability to interfere with topoisomerase II (TOP2) and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy. Can recent studies lead to refined targeting of TOP2 and an improved anticancer strategy?
It has become clear that cell–cell signalling — known as the bystander effect — has an important role in responses to ionizing radiation. What do we know about this effect and how might it affect the response to radiotherapy?
Tumour necrosis factor (TNF) was initially isolated as a factor that induced necrosis of cancer cells. However, it has become clear that TNF can also promote cancer. This Timeline examines the long history of TNF in cancer biology, asking whether it is a target, a therapeutic or both.
The complex web of regulation that surrounds the tumour suppressor p53 is well known, but few have considered the effect that this has on the dynamics of p53 itself. This forward-looking Perspective speculates on the insights that we might gain by examining the p53 dynamics in individual tumour cells.
